FiercePharma

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
FiercePharma

U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia

TITUSVILLE, N.J., May 19, 2015 / PR Newswire / — There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only schizophrenia medication to ...
Nasdaq

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

DUBLIN, April 9, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a ...
Business Insider

Invega Sustenna/Trinza (Paliperidone Palmitate; Johnson & Johnson) Drug Overview & Product Profiles 2018

The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering. Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are ...
Medscape

FDA Approves Once-Monthly Paliperidone Palmitate Injection for Treating Schizophrenia

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...
Monthly Prescribing Reference

Significant Improvement in Schizophrenia Symptoms After Antipsychotic Injectable Switch

The 6-month study examined the safety, efficacy, and tolerability of Aristada in patients with schizophrenia who had an inadequate response or intolerance to Invega Sustenna. The 6-month, open-label, ...
Business Insider

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...
Nasdaq

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...
Monthly Prescribing Reference

Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...
Chicago Tribune

Saying ‘I Can’ to Making a Difference With Schizophrenia

Tanara never thought she’d be where she is today. Leading up to and following her diagnosis with schizophrenia, she often felt alone — her symptoms led her to isolate herself from her friends, family, ...
Yahoo Finance

Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

UZEDY ® (1-month and 2-month subcutaneous risperidone for treatment of schizophrenia), is the first product based on Medincell's long-acting injection technology that reached commercial stage. UZEDY ...